292 related articles for article (PubMed ID: 8634009)
21. Tardive dyskinesia in schizophrenics under 60 years of age.
Kolakowska T; Williams AO; Ardern M; Reveley MA
Biol Psychiatry; 1986 Feb; 21(2):161-9. PubMed ID: 2868762
[TBL] [Abstract][Full Text] [Related]
22. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.
Tollefson GD; Beasley CM; Tamura RN; Tran PV; Potvin JH
Am J Psychiatry; 1997 Sep; 154(9):1248-54. PubMed ID: 9286184
[TBL] [Abstract][Full Text] [Related]
23. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
Gharabawi GM; Bossie CA; Zhu Y; Mao L; Lasser RA
Schizophr Res; 2005 Sep; 77(2-3):129-39. PubMed ID: 15913962
[TBL] [Abstract][Full Text] [Related]
24. Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naïve patients.
Woerner MG; Correll CU; Alvir JM; Greenwald B; Delman H; Kane JM
Neuropsychopharmacology; 2011 Jul; 36(8):1738-46. PubMed ID: 21508932
[TBL] [Abstract][Full Text] [Related]
25. Tardive dyskinesia and type II schizophrenia.
Davis EJ; Borde M; Sharma LN
Br J Psychiatry; 1992 Feb; 160():253-6. PubMed ID: 1347240
[TBL] [Abstract][Full Text] [Related]
26. A 10-year follow-up study of tardive dyskinesia.
Yassa R; Nair NP
Acta Psychiatr Scand; 1992 Oct; 86(4):262-6. PubMed ID: 1360742
[TBL] [Abstract][Full Text] [Related]
27. The current prevalence and factors associated with tardive dyskinesia among Filipino schizophrenic patients.
Go CL; Rosales RL; Caraos RJ; Fernandez HH
Parkinsonism Relat Disord; 2009 Nov; 15(9):655-9. PubMed ID: 19346155
[TBL] [Abstract][Full Text] [Related]
28. Prospective study of tardive dyskinesia incidence in the elderly.
Saltz BL; Woerner MG; Kane JM; Lieberman JA; Alvir JM; Bergmann KJ; Blank K; Koblenzer J; Kahaner K
JAMA; 1991 Nov; 266(17):2402-6. PubMed ID: 1681122
[TBL] [Abstract][Full Text] [Related]
29. Treatment programme and long-term outcome in chronic schizophrenia.
Kane JM
Acta Psychiatr Scand Suppl; 1990; 358():151-7. PubMed ID: 1978476
[TBL] [Abstract][Full Text] [Related]
30. Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia.
Caroff SN; Mu F; Ayyagari R; Schilling T; Abler V; Carroll B
BMC Psychiatry; 2018 Sep; 18(1):306. PubMed ID: 30249218
[TBL] [Abstract][Full Text] [Related]
31. Association of negative symptoms with tardive dyskinesia in schizophrenic patients.
Chiu H; Lau J; Lam L; Shum P
Aust N Z J Psychiatry; 1993 Jun; 27(2):228-32. PubMed ID: 8103320
[TBL] [Abstract][Full Text] [Related]
32. Tardive dyskinesia.
Jeste DV; Caligiuri MP
Schizophr Bull; 1993; 19(2):303-15. PubMed ID: 8100643
[TBL] [Abstract][Full Text] [Related]
33. Tardive dyskinesia: who is at risk?
van Os J; Fahy T; Jones P; Harvey I; Toone B; Murray R
Acta Psychiatr Scand; 1997 Sep; 96(3):206-16. PubMed ID: 9296552
[TBL] [Abstract][Full Text] [Related]
34. Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia.
Sirota P; Mosheva T; Shabtay H; Giladi N; Korczyn AD
Am J Psychiatry; 2000 Feb; 157(2):287-9. PubMed ID: 10671405
[TBL] [Abstract][Full Text] [Related]
35. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone.
Jeste DV; Okamoto A; Napolitano J; Kane JM; Martinez RA
Am J Psychiatry; 2000 Jul; 157(7):1150-5. PubMed ID: 10873925
[TBL] [Abstract][Full Text] [Related]
36. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction.
Margolese HC; Chouinard G; Kolivakis TT; Beauclair L; Miller R
Can J Psychiatry; 2005 Aug; 50(9):541-7. PubMed ID: 16262110
[TBL] [Abstract][Full Text] [Related]
37. Treatment of late-life schizophrenia with neuroleptics.
Jeste DV; Lacro JP; Gilbert PL; Kline J; Kline N
Schizophr Bull; 1993; 19(4):817-30. PubMed ID: 7905663
[TBL] [Abstract][Full Text] [Related]
38. A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia.
Goff DC; Renshaw PF; Sarid-Segal O; Dreyfuss DA; Amico ET; Ciraulo DA
Biol Psychiatry; 1993 May; 33(10):700-6. PubMed ID: 8102552
[TBL] [Abstract][Full Text] [Related]
39. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial.
Miller DD; McEvoy JP; Davis SM; Caroff SN; Saltz BL; Chakos MH; Swartz MS; Keefe RS; Rosenheck RA; Stroup TS; Lieberman JA
Schizophr Res; 2005 Dec; 80(1):33-43. PubMed ID: 16171976
[TBL] [Abstract][Full Text] [Related]
40. Atypical antipsychotic drugs and tardive dyskinesia: relevance of D2 receptor affinity.
Bressan RA; Jones HM; Pilowsky LS
J Psychopharmacol; 2004 Mar; 18(1):124-7. PubMed ID: 15107196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
